콘텐츠로 건너뛰기
Merck
모든 사진(2)

주요 문서

SAB4300058

Sigma-Aldrich

Anti-phospho-ERBB2 (pTyr1221/pTyr1222) antibody produced in rabbit

affinity isolated antibody

동의어(들):

Anti-CD340 antibody produced in rabbit, Anti-HER-2 antibody produced in rabbit, Anti-HER-2/neu antibody produced in rabbit, Anti-HER2 antibody produced in rabbit, Anti-v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro / glioblastoma derived oncogene homolog (avian) antibody produced in rabbit

로그인조직 및 계약 가격 보기


About This Item

UNSPSC 코드:
12352203
NACRES:
NA.41

생물학적 소스

rabbit

Quality Level

결합

unconjugated

항체 형태

affinity isolated antibody

항체 생산 유형

primary antibodies

클론

polyclonal

양식

buffered aqueous solution

분자량

~185 kDa

종 반응성

human

농도

1 mg/mL

기술

indirect immunofluorescence: 1:100-1:200
western blot: 1:500-1:1000

동형

IgG

면역원 서열

(N-L-YP-YP-W)

NCBI 수납 번호

UniProt 수납 번호

배송 상태

wet ice

저장 온도

−20°C

타겟 번역 후 변형

phosphorylation (pTyr1221/pTyr1222)

유전자 정보

human ... ERBB2(2064)

일반 설명

Erb-b2 receptor tyrosine kinase 2 (ErbB2) or human epidermal growth factor receptor 2 (HER2), is encoded by the gene mapped to human chromosome 17. The encoded protein belongs to the family of epidermal growth factors. ErbB2 membrane protein is characterized with a cysteine-rich extracellular ligand-binding domain, a hydrophobic membrane spanning region, and an intracellular tyrosine kinase domain.This protein does not have a ligand, and it either forms heterodimers with other family members or homodimer with itself when expressed at very high levels, to get activated. ErbB2 is expressed at low level in normal tissues, but at high level in breast cancer tissues.

면역원

Peptide sequence around phosphorylation site of tyrosine1221/1222 (N-L-Y(p)-Y(p) -W), according to the protein ERBB2.

생화학적/생리학적 작용

Erb-b2 receptor tyrosine kinase 2 (ErbB2) signaling pathway stimulates cell proliferation and survival in the majority of breast cancers. Thus, over expression of this protein causes breast cancer. Heterodimer complex of ErbB2 and phosphatidylinositide 3-kinase (PI3K) is the most potent stimulator of the PI3K/AKT anti-apoptosis pathway. Increased expression of ErbB2 is also observed in ovarian, colorectal, pancreatic, endometrial and gastric cancers. Trastuzumab, an antibody, works by binding to a domain in the external domain of ErbB2. This domain is missing in p95, a truncated form of ErbB2, and hence these cancer cells show resistance to trastuzumab. ErbB2 protein can be used as a prognostic marker and as a therapeutic option for gynecologic cancers.

특징 및 장점

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

표적 설명

Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Not activated by EGF, TGF-alpha and amphiregulin.

물리적 형태

Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol

면책조항

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

적합한 제품을 찾을 수 없으신가요?  

당사의 제품 선택기 도구.을(를) 시도해 보세요.

Storage Class Code

10 - Combustible liquids

WGK

WGK 1

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, 21, 382-389 (2016)
HER2: biology, detection, and clinical implications.
Gutierrez C and Schiff R.
Archives of Pathology & Laboratory Medicine, 135, 55-62 (2011)
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.
English DP
Molecular Diagnosis & Therapy, 17, 85-99 (2013)
Toshio Shimizu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(19), 5032-5040 (2014-08-12)
This first-in-human phase I study evaluated dose-limiting toxicities (DLT) and defined a phase II recommended dose (RD) for CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 as a 1-hour intravenous (i.v.) infusion for 5 consecutive days every 2 weeks.
Yong Sang Hong et al.
PloS one, 9(10), e109440-e109440 (2014-10-29)
ERBB2-directed therapy is now a routine component of therapy for ERBB2-amplified metastatic gastroesophageal adenocarcinomas. However, there is little knowledge of the mechanisms by which these tumors develop acquired resistance to ERBB2 inhibition. To investigate this question we sought to characterize

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.